---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042663"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T19:11:43.785205+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q1 net loss narrows to $636K; license revenue up 26%

## Summary
- Net loss from continuing ops $(636)K ($0.06/sh) vs $(809)K ($0.07/sh) in Q1 2024.
- License revenue $393K, up 25.8% from $313K, driven by Mayne License sales changes.
- Operating expenses $1,264K, down 13.1% from prior year on royalty business efficiencies.
- Cash and equivalents $5.7M at March 31, 2025; no debt disclosed.
- Company continues evaluating strategic alternatives including M&A or asset sale.

## SEC filing metadata
- accession: 0001213900-25-042663
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390025042663/0001213900-25-042663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390025042663/ea0241986-8k_therap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042663
- JSON: https://secwatch.observer/filing/0001213900-25-042663.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.